Brand name drugs and generic drugs at war

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Since the beginning of 2006, the economic and legal war between laboratories and generics companies has seen new developments, which lead us to update our study published in issue 1-2006 of this journal. We will focus our attention on two types of behavior that have recently come to the attention of antitrust authorities and courts across the Atlantic: the launch of clean generics by laboratories during the exclusivity period enjoyed by the first generic company to obtain an ANDA under "paragraph IV"; and the multiplication of deferred entry agreements between generic companies and laboratories. I- The battle of clean generics In the United States, the